Show simple item record

dc.contributor.authorKirby, AM
dc.contributor.authorGuckenberger, M
dc.contributor.authorSlotman, BJ
dc.contributor.authorClark, CH
dc.contributor.authorEriksen, JG
dc.contributor.authorvan der Heide, U
dc.contributor.authorDe Ioanna, S
dc.contributor.authorGasparotto, C
dc.contributor.authorCortese, AJ
dc.contributor.authorESTRO Board of Directors
dc.coverage.spatialIreland
dc.date.accessioned2024-07-03T12:32:29Z
dc.date.available2024-07-03T12:32:29Z
dc.date.issued2024-07-01
dc.identifierARTN 110283
dc.identifierS0167-8140(24)00205-6
dc.identifier.citationRadiotherapy and Oncology, 2024, 196 pp. 110283 -en_US
dc.identifier.issn0167-8140
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/6279
dc.identifier.eissn1879-0887
dc.identifier.eissn1879-0887
dc.identifier.doi10.1016/j.radonc.2024.110283
dc.identifier.doi10.1016/j.radonc.2024.110283
dc.description.abstractIn 2019, the European Society of Radiotherapy and Oncology (ESTRO) published its 2030 Vision "Radiation Oncology, Optimal Health, For All, Together". However, in 2020, the global pandemic, coinciding with the Society's 40th anniversary, had long-term consequences on global behaviours and on the financial environment for scientific associations worldwide. In 2022, ESTRO conducted a survey among its members, revealing their strong appreciation for networking opportunities and the creation of high-quality interdisciplinary scientific content. In response to the survey findings and to address the evolving landscape following the COVID pandemic, ESTRO initiated a strategic review process to respond to, and refocus on, the opportunities and challenges ahead. This paper, marking a turning point in ESTRO's strategy for achieving its Vision 2030 in a post-pandemic era, describes the 2022-23 strategic review process, discussions, and consequent recommendations. The comprehensive strategic review process involved: (i) pre-meeting preparations with surveys and strategic documents; (ii) a carefully themed three-day retreat in Brussels incorporating a blend of plenary sessions, workshops focusing on ESTRO's role, value creation and capture, strategic objectives; and (iii) a post-retreat phase including qualitative analysis and development of action plans. The strategic review emphasized the need for adaptive tactics for scientific associations to remain current and productive in the face of changing global conditions. The development of key strategic goals for the years 2024-2026 focused on improving research impact, strengthening and diversifying ESTRO's educational offerings and fostering proactive and mutually beneficial partnerships. The Board approved these objectives, alongside prioritising digital innovation, financial sustainability, and community engagement for ESTRO's continued growth and development. In essence, ESTRO aims to advocate, empower, expand, and diversify its community, with the overarching goal of enhancing cancer care for patients in Europe, and beyond.
dc.formatPrint-Electronic
dc.format.extent110283 -
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIER IRELAND LTDen_US
dc.relation.ispartofRadiotherapy and Oncology
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.subjectHumans
dc.subjectRadiation Oncology
dc.subjectSocieties, Medical
dc.subjectEurope
dc.subjectCOVID-19
dc.subjectMedical Oncology
dc.subjectPandemics
dc.subjectSARS-CoV-2
dc.titleEuropean Society of Radiotherapy and Oncology (ESTRO) strategy 2024-2026: Growth and diversification in a rapidly changing world.en_US
dc.typeJournal Article
dcterms.dateAccepted2024-04-13
dc.date.updated2024-07-03T12:31:41Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.radonc.2024.110283en_US
rioxxterms.licenseref.startdate2024-07-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/38641262
pubs.organisational-groupICR
pubs.organisational-groupICR/Primary Group
pubs.organisational-groupICR/Primary Group/ICR Divisions
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy
pubs.organisational-groupICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-groupICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.)
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.radonc.2024.110283
pubs.volume196
dc.contributor.icrauthorKirby, Anna
icr.provenanceDeposited by Mr Arek Surman on 2024-07-03. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0167814024002056-main.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/